Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
JPH0436136B2 - - Google Patents
[go: Go Back, main page]

JPH0436136B2 - - Google Patents

Info

Publication number
JPH0436136B2
JPH0436136B2 JP59043184A JP4318484A JPH0436136B2 JP H0436136 B2 JPH0436136 B2 JP H0436136B2 JP 59043184 A JP59043184 A JP 59043184A JP 4318484 A JP4318484 A JP 4318484A JP H0436136 B2 JPH0436136 B2 JP H0436136B2
Authority
JP
Japan
Prior art keywords
tonic
effects
test
stress
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP59043184A
Other languages
Japanese (ja)
Other versions
JPS60188326A (en
Inventor
Yoshiaki Nakai
Naoki Imoto
Toshio Murakami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Pharmaceutical Co Ltd
Original Assignee
Daiichi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Pharmaceutical Co Ltd filed Critical Daiichi Pharmaceutical Co Ltd
Priority to JP59043184A priority Critical patent/JPS60188326A/en
Publication of JPS60188326A publication Critical patent/JPS60188326A/en
Publication of JPH0436136B2 publication Critical patent/JPH0436136B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

【発明の詳細な説明】[Detailed description of the invention]

本発明はパンテチン、朝鮮人参及びビタミンE
の三成分を配合した滋養強壮剤に関する。 本発明の滋養強壮剤は、又アルコール代謝改
善、冷え性改善、不定愁訴の改善にも有効な薬剤
である。 近年、高令化社会の進行に伴ない、或は社会構
造の複雑化に伴ない特に熟年以後の健康管理は重
要な社会問題となつており、そのために各種滋養
強壮剤が開発されている。 滋養強壮を目的とした薬剤には、漢方処方に基
づく製剤、生薬を主剤とする製剤、総合ビタミン
剤、ビタミン類にアミノ酸、生薬、臓器抽出物等
を配合した製剤等があり、セルフ・メデイケーシ
ヨンの一環として健康維持・増進をめざし服用さ
れている。しかし、これら滋養強壮を目的とした
薬剤には、アルコール代謝の改善に有効なものは
ない。 そこで、本発明者等は、従来の滋養強壮剤には
認められなかつた効果を有する滋養強壮剤の開発
をめざし鋭意検討した結果本発明を完成した。即
ち、本発明の滋養強壮剤は滋養強壮効果に加え、
優れたアルコール代謝改善作用を有し、かつ又冷
え症の改善及び不定愁訴の改善にも非常に有効な
ものであり、かかる作用効果を有する滋養強壮剤
は従来には認められなかつた極めて特徴的なもの
である。更に詳細に述べれば、本発明の滋養強壮
剤の有効成分である三成分は各々公知の物質であ
り、従来独立して使用されている。即ち、パンテ
チンは脂質代謝改善剤として著名な医薬品であ
り、朝鮮人参は各種薬理効果をあわせもつものと
して滋養強壮剤として古くより使われており、又
ビタミンEは抗酸化作用による動脈硬化の防止、
栄養障害の改善等に使用されている。 しかるに、これ等公知の化合物を適切に配合し
た合剤を製した場合、それぞれの単独使用におけ
る効果よりはるか優れた効果を期待しうること、
及び単独使用では期待しえなかつた効果、例えば
アルコール代謝の改善、冷え症改善、不定愁訴の
改善等に有効なことを見いだし本発明の滋養強壮
剤を完成したものである。 本発明の滋養強壮剤を製するには、パンテチ
ン、朝鮮人参及びビタミンEの三成分を適量比で
混合し、必要ならば通常使用される適当なる製剤
上の添加剤、たとえば、トウモロコシデンプン、
カルボキシルメチルセルロース等を加え好ましい
剤型、すなわち錠剤、顆粒剤、カプセル剤とすれ
ばよい。混合比としては前三者の比を約1:2〜
15:0.05〜0.3とするのが好ましく、この際使用
される各主成分は下記のものが使用される。 即ち、パンテチンは含量規格で90〜115%のも
のが、ビタミンEは同じく90〜110%のものが使
用され、朝鮮人参は日局規格(第10改正)に適す
るニンジン(人参)、コウジン(紅参)が使用し
え、サポニン含量が安定した4〜6年ものが好ま
しく使用される。 本発明の滋養強壮剤は、通常経口投与され、そ
の投与量は前記の如き三成分の比とした場合に
は、1日450mg程度とすればよい。 かくして製した本発明の滋養強壮剤が通常の流
通保存環境条件下では安定であることを室温及び
40℃、75%R,Hの条件下における安定試験(外
観、確認試験、含量、崩壊試験及び吸湿増量)で
確認した。 又、本発明の滋養強壮剤の安全性についても検
討した結果、極めて安全であることを確認した。
即ち、ddY系マウス雌雄1群各10匹に、薬物2.5
g/Kg、5.0g/Kgを0.5%CMCに懸濁し経口投与
した急性毒性試験の結果LD50値は5g/Kg以上
であつた。即ち、両薬剤群とも実験期間中死亡例
が見られず、14日間の観察期間を通じて行動及び
外観の異常は観察されなかつた。又、屠殺後の剖
検による肉眼的所見にも何ら異常は認められなか
つた。又、ddY系マウスを用いた正常動物の行動
に及ぼす影響にて単回投与並びに連続20日間投与
ともに、躯幹緊張度、握力、運動協調性、自発運
動量及び探索動作等コントロール群と何らの差が
認められなかつた。 又、健康人12名に1日量の1.5倍量を運動負荷
後8日間連続投与した臨床薬理試験にて何らの副
作用も認められなかつた。 更に、後述する約200名の臨床評価試験にて、
2例に軽度の胃腸症状が認められたのみであり、
極めて安全な薬剤であつた。 本発明滋養強壮剤の優れた効果は、下記試験例
にて具体的に示される。 試験例 1:基礎薬理試験 動物にアルコール負荷のほか強制運動(ロープ
登り)、水上宙吊り、水没拘束などの種々のスト
レスを負荷し、これに対する薬剤の影響を行動薬
理学的指標等を用いて検討した。 使用した薬剤と投与量(mg/Kg P.O) 本配合剤(Aと略す):450,225 パンテチン(Pと略す):90 乾燥コウジンエキス(Gと略す):250 酢酸d−α−トルフエロール(Tと略す):50 (1) 「アルコール代謝の改善」に関連した薬理作
用 アルコール負荷に対する運動協調性試験
(回転棒) アルコール負荷からの回復の状態を知る目的
でマウスに40%アルコール0.1ml/10g体重(人
体換算:ウイスキーボトル約1本相当を経口投与
し、回転棒(ロー上の滞在時間を経時的に測定し
て運動の回復度を検討した。 結果は表−1に示される如く本試験において効
果のすぐれた(有意差のある)成分はハンテチン
(P)であつたが、配合剤(A)に相乗効果が見られ
た。
The present invention provides pantethine, ginseng and vitamin E.
This article relates to a nourishing tonic containing three ingredients. The nutritional tonic of the present invention is also effective for improving alcohol metabolism, improving sensitivity to cold, and improving indeterminate complaints. In recent years, with the advancement of an aging society and the increasing complexity of social structures, health management, especially after middle age, has become an important social issue, and various nutritional tonics have been developed for this purpose. Drugs aimed at nourishing and tonic include preparations based on Chinese herbal prescriptions, preparations based on herbal medicines, multivitamins, and preparations containing vitamins, amino acids, herbal medicines, organ extracts, etc., and self-medication. It is taken as part of the medicine to maintain and improve health. However, none of these nutritional and tonic drugs are effective in improving alcohol metabolism. Therefore, the present inventors completed the present invention as a result of intensive studies aimed at developing a nutritious tonic with effects not found in conventional nutritious tonics. That is, the nutritious tonic of the present invention has a nutritious and tonic effect,
It has an excellent effect on improving alcohol metabolism, and is also very effective in improving sensitivity to cold and indeterminate complaints, and it is a very unique tonic that has not been recognized before. It is something. More specifically, each of the three active ingredients of the nutritional tonic of the present invention is a known substance and has been used independently in the past. In other words, pantethine is a well-known drug as a lipid metabolism improver, Panax ginseng has been used for a long time as a nutritional tonic and has various pharmacological effects, and vitamin E has antioxidant effects that prevent arteriosclerosis.
It is used to improve malnutrition, etc. However, if a mixture of these known compounds is prepared in an appropriate manner, it can be expected that the effects will be far superior to those obtained when each is used alone.
Furthermore, we have completed the nutritional tonic of the present invention by discovering that it is effective in improving alcohol metabolism, improving sensitivity to cold, and improving indeterminate complaints, etc., which could not be expected when used alone. To prepare the nutritional tonic of the present invention, the three components of pantethine, ginseng, and vitamin E are mixed in an appropriate ratio, and if necessary, suitable pharmaceutical additives commonly used, such as corn starch,
Carboxylmethylcellulose or the like may be added to form a preferred dosage form, ie, tablets, granules, or capsules. The mixing ratio of the former three is about 1:2~
15: It is preferable to set it as 0.05-0.3, and each main component used in this case is the following. In other words, pantethine is used with a content of 90 to 115% according to the content standard, vitamin E is used with a content of 90 to 110%, and Korean ginseng is used with ginseng and red ginseng, which meet the Japanese standards (10th revision). ) can be used, and those with a stable saponin content of 4 to 6 years are preferably used. The nutrient tonic of the present invention is usually orally administered, and the dosage may be about 450 mg per day when the three components are in the ratio as described above. It was confirmed that the nutritional tonic of the present invention thus prepared is stable under normal distribution and storage environmental conditions at room temperature and
Confirmed by stability test (appearance, confirmation test, content, disintegration test, and increase in moisture absorption) under the conditions of 40°C and 75% R and H. Furthermore, as a result of examining the safety of the nutritional tonic of the present invention, it was confirmed that it is extremely safe.
That is, each group of 10 male and female ddY mice was given 2.5 ml of the drug.
As a result of an acute toxicity test in which 5.0 g/Kg was suspended in 0.5% CMC and orally administered, the LD 50 value was 5 g/Kg or more. That is, in both drug groups, no deaths were observed during the experimental period, and no abnormalities in behavior or appearance were observed throughout the 14-day observation period. In addition, no abnormalities were observed in the macroscopic findings of the post-slaughter autopsy. In addition, regarding the effects on the behavior of normal animals using ddY mice, both single administration and continuous administration for 20 days showed no difference from the control group in terms of trunk tension, grip strength, motor coordination, locomotor activity, and exploratory movements. It wasn't recognized. In addition, no side effects were observed in a clinical pharmacology study in which 1.5 times the daily dose was administered to 12 healthy subjects for 8 consecutive days after exercise stress. Furthermore, in a clinical evaluation test of approximately 200 people described below,
Only mild gastrointestinal symptoms were observed in 2 cases;
It was an extremely safe drug. The excellent effects of the nutrient tonic of the present invention are specifically demonstrated in the following test examples. Test Example 1: Basic Pharmacology Test In addition to alcohol loading, animals are subjected to various types of stress such as forced exercise (rope climbing), suspended above water, and submerged restraint, and the effects of drugs on this stress are investigated using behavioral pharmacological indicators. did. Drugs used and dosage (mg/Kg PO) This combination drug (abbreviated as A): 450, 225 Pantethine (abbreviated as P): 90 Dried red ginseng extract (abbreviated as G): 250 d-α-tolferol acetate (abbreviated as T) ): 50 (1) Pharmacological effects related to "improvement of alcohol metabolism" Motor coordination test in response to alcohol load (rotating rod) 0.1ml/10g of 40% alcohol was administered to mice for the purpose of determining the state of recovery from alcohol load. Body weight (human body equivalent: equivalent to about one whiskey bottle) was orally administered, and the time spent on a rotating bar (row) was measured over time to examine the degree of recovery from exercise.The results are shown in Table 1. The component with superior effects (with a significant difference) was huntetin (P), but a synergistic effect was observed in combination drug (A).

【表】 (2) 「冷え症の改善」に関連した薬理作用 宙吊りによる体温(直腸温)低下に対する
拮抗 マウスを水上に宙吊りすると疲労と水の
ため体温低下を起すが、これに対する薬剤の
影響を見た。 水上宙吊りストレス負荷後の体温低下抑制に関
しては、各単味成分に有意の効果は認められなか
つたが、配合剤(A)では有意の効果が見られた。
[Table] (2) Pharmacological effects related to "improvement of sensitivity to cold" Antagonism to the drop in body temperature (rectal temperature) due to suspension When a mouse is suspended above water, it causes a drop in body temperature due to fatigue and water, but we investigated the effects of drugs on this. Ta. Regarding the suppression of body temperature drop after the stress of hanging above water, no significant effect was observed for each single ingredient, but a significant effect was observed for combination drug (A).

【表】 (3) 「不定愁訴の改善」に関連した薬理作用 ストレス潰瘍に対する抑制作用 ラツトに水没拘束による強いストレスを加
え、そのために生ずる胃潰瘍を指標として本
配合剤の効果を検討した。 実験方法 ラツト(1群):10匹(単回投与)、 12匹(連続10回投与) 水中拘束時間 :7時間 薬剤投与量 P:100,300mg/Kg G:300,1000mg/Kg T:100,300mg/Kg A:450mg/Kg(常用量の60倍) 効果の判定 水没拘束後直ちに開腹して胃壁に生じた潰瘍に
つき赤色部(炎症部)と黒色陥凹部(びらん部)
にわけ、潰瘍指数(Ulcer index)によつて評価
した。 水没拘束ストレスによる潰瘍の抑制作用は、単
味成分では大量トコフエロール(T.100mg)に認
められた程度で全般に弱かつた。 しかし、配合剤(A)は、単回投与、連続投与共に
有意の差をもつて有効性が認められた。
[Table] (3) Pharmacological effects related to "improvement of indeterminate complaints" Suppressing effect on stress ulcers Rats were subjected to strong stress by being submerged in water, and the effects of this combination drug were investigated using the resulting gastric ulcers as an indicator. Experimental method Rats (group 1): 10 (single dose), 12 (10 consecutive doses) Water restraint time: 7 hours Drug dosage P: 100, 300 mg/Kg G: 300, 1000 mg/Kg T: 100 , 300mg/Kg A: 450mg/Kg (60 times the usual dose) Judgment of effectiveness Immediately after submersion restraint, the abdomen was opened and the ulcer formed on the stomach wall had a red area (inflammation area) and a black depressed area (erosion area).
In particular, it was evaluated using the Ulcer index. The inhibitory effect on ulcers caused by water immersion restraint stress was generally weak among single ingredients, to the extent that it was observed in large amounts of tocopherol (T.100mg). However, combination drug (A) was found to be effective with a significant difference in both single administration and continuous administration.

【表】【table】

【表】【table】

【表】 (4) 「滋養強壮」に関連した薬理作用 強制運動負荷に対する影響(ロープ登り) マウスを用いて毎日1時間、14日連続して
ロープ登り運動(登上距離4m/分、240m/
時)をさせ薬剤は毎日運動後に与えその遂行
能力(疲労回復度)を検討した。 長期間(14日)、連続の強制運動(ロープ登り)
からの回復に関しては、配合剤(A)は有意の差をも
つて有効であつた。特にその傾向は、後半期に顕
著であつた。
[Table] (4) Pharmacological effects related to "Nourishment tonic" Effect on forced exercise load (rope climbing) Mice were subjected to rope climbing exercise for 1 hour every day for 14 consecutive days (climbing distance 4 m/min, 240 m/min)
The drug was administered every day after exercise to examine performance performance (degree of recovery from fatigue). Long term (14 days), continuous forced exercise (rope climbing)
Concerning recovery from , combination drug (A) was significantly more effective. This trend was especially noticeable in the latter half of the year.

【表】 水上宙吊り後の学習の再現に対する影響(明
暗箱法) 学習させたマウスを1日1時間4日連続鼻
面が水面に接するように宙吊りし、激しいス
トレスと疲労後に薬剤を与えて明暗箱を用い
て学習の再現をさせその記憶度を検討した。
[Table] Effects on reproduction of learning after suspension above water (light/dark box method) Mice that have been trained are suspended in the air with their nose touching the water surface for 1 hour a day for 4 consecutive days, and after severe stress and fatigue, a drug is given to them and a light/dark box method is used. The students were asked to reproduce what they had learned using the software, and their memorability was examined.

【表】 なお、水上宙吊りストレス負荷後の記憶の再現
試験で、有効性の認められた単味成分は人参
(G)のみであつたが、配合剤(A)も有意差をもつ
て有効であつた。 水上宙吊り後の性行動障害からの回復に対す
る影響 マウスを1日30分〜2時間連続14日間と
同様にして水上に宙吊りし、その激しいスト
レスと疲労を与えた後、薬剤を与え、翌朝の
性行動の度合い(ウマ乗り運動、挿入回数)
を検討した。 水上宙吊りストレス負荷後の性行動障害からの
回復に対しては配合剤(A)は有意に有効であつた。
[Table] In addition, in the memory reproduction test after stress loading by hanging above water, the only single ingredient that was found to be effective was ginseng (G), but the combination drug (A) was also found to be effective with a significant difference. It was hot. Effects on recovery from sexual behavior disorder after suspension over water Mice were suspended over water for 30 minutes to 2 hours a day for 14 consecutive days, giving them severe stress and fatigue. Degree of activity (mounting motion, number of insertions)
It was investigated. Combination drug (A) was significantly effective for recovery from sexual behavior disorder after stress of hanging above water.

【表】【table】

【表】 試験例 2:臨床評価試験 予備試験の結果、本配合剤の有効性と安全性に
ついての予測が得られたので、全国8機関で本試
験が実施された。同一プロトコール、調査表(医
師用)、健康に関するアンケート用紙(患者用)
にて全例196例を収集し、解析・評価した結果は
以下の如くである。 総合評価では、やや改善以上が82.5%で改善以
上でも37.6%を示した。 症状別効果では食欲不振、悪酔い、腰痛、イラ
イラ感、冷え、便秘等に有効性がみられた。投与
前重症度別改善度ではほとんどの症状において、
重症度の高いものほど投与後改善度が大であつ
た。性別では女性の方は、疲労感、肩こり等が、
男性の方は心悸亢進等の改善がより大であつた。
[Table] Test Example 2: Clinical Evaluation Test As a result of the preliminary test, predictions regarding the efficacy and safety of this combination drug were obtained, and the main test was conducted at 8 institutions nationwide. Same protocol, survey form (for doctors), health questionnaire form (for patients)
A total of 196 cases were collected, analyzed and evaluated, and the results are as follows. In the overall evaluation, 82.5% said it was slightly improved and 37.6% said it was improved or better. In terms of effectiveness by symptom, it was found to be effective for loss of appetite, drunkenness, lower back pain, irritability, feeling cold, and constipation. Regarding the degree of improvement by severity before administration, for most symptoms,
The degree of improvement after administration was greater in cases with higher severity. Regarding gender, women experience fatigue, stiff shoulders, etc.
The improvement in heart palpitations was greater in men.

【表】【table】

【表】【table】

【表】【table】

Claims (1)

【特許請求の範囲】[Claims] 1 パンテチン、朝鮮人参及びビタミンEの三成
分を配合した滋養強壮剤
1. A nourishing tonic containing three ingredients: pantethine, ginseng, and vitamin E.
JP59043184A 1984-03-07 1984-03-07 Ternary composition Granted JPS60188326A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP59043184A JPS60188326A (en) 1984-03-07 1984-03-07 Ternary composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP59043184A JPS60188326A (en) 1984-03-07 1984-03-07 Ternary composition

Publications (2)

Publication Number Publication Date
JPS60188326A JPS60188326A (en) 1985-09-25
JPH0436136B2 true JPH0436136B2 (en) 1992-06-15

Family

ID=12656817

Family Applications (1)

Application Number Title Priority Date Filing Date
JP59043184A Granted JPS60188326A (en) 1984-03-07 1984-03-07 Ternary composition

Country Status (1)

Country Link
JP (1) JPS60188326A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1069A (en) * 1996-06-13 1998-01-06 Arusoa Oushiyou:Kk Binder for processed food and processed food using the same
JPH1070A (en) * 1996-06-13 1998-01-06 Arusoa Oushiyou:Kk Processed foods useful for beauty and health

Also Published As

Publication number Publication date
JPS60188326A (en) 1985-09-25

Similar Documents

Publication Publication Date Title
US6811796B2 (en) Preventive or therapeutic agent for pollen allergy, allergic rhinitis, atopic dermatitis, asthma or urticaria, or health food for prevention or improvement or reduction of symptoms thereof
Morrison et al. Vitamin absorption studies: I. Factors influencing the excretion of oral test doses of thiamine and riboflavin by human subjects
JPH0432802B2 (en)
KR19990044460A (en) Use of thienotriazolodiazepine to increase the amount of apolipoprotein A-eye
EP1997496A1 (en) Composition containing riboflavin and sesamins
US4464394A (en) Compositions and methods for using 13-cis vitamin A acid compounds
AU2016253140B2 (en) Plant extracts for the treatment of excess weight and obesity
CA2077589A1 (en) Cerebral-activating extract
DE69806788T2 (en) COMPOSITION FOR THE SUPPRESSION OF WITHDRAWAL SYMPTOMS AND ALCOHOL DEPENDENCY IN ALCOHOLICIANS AND PREVENTION OF ALCOHOL ABUSE IN HEALTHY PERSONS
US4594249A (en) Method of altering intoxicating effects of alcohol
White et al. A pharmacokinetic comparison of two delayed-release peppermint oil preparations, Colpermin and Mintec, for treatment of the irritable bowel syndrome
JPH05262660A (en) Tricomponent formulation
JPH0436136B2 (en)
US4721716A (en) Method for desensitizing the gastrointestinal tract from food allergies
US5948824A (en) Use of a chemical agent for reducing the changes in waistline and the effect of constipation due to the taking of other agents
RU2189243C1 (en) Compositions "ginrosin" showing general tonic and adaptogenic effect
JP5282202B2 (en) Anti-stress agent or sleep-improving agent
US6506420B2 (en) Combinations of psyllium and chitosan for synergistic adsorption of triglyceride
KR100208969B1 (en) Anti-ulcer agent containing glutinous rice extract
Simon et al. Administration of obidoxime tablets to man: plasma levels and side reactions
JP5601747B2 (en) Composition for internal use for fatigue prevention and preparation for internal use for fatigue prevention
Haugen Double blind cross-over study of a new appetite suppressant AN 448
US4446132A (en) Nontoxic aspirin composition
KR20030087383A (en) Using β-glucan of yeast cell wall for health
MXPA03009631A (en) Composition for the prevention or treatment of learning disorders in children suffering from attention deficit/hyperactive disorder.

Legal Events

Date Code Title Description
EXPY Cancellation because of completion of term